Summary of a Workshop on the Role of Third-Party Payers in Clinical Trials of New Agents

Publisher Website
Google Scholar
Abstract
Today's proliferation of highly technical and expensive methods of treating patients with chronic diseases led officials of the Arthritis Foundation and National Multiple Sclerosis Society to sponsor a workshop exploring methods of payment for clinical trials, at Airlie House, Airlie, Virginia, July 5 through 7. Among the 80 persons attending were representatives of the following organizations and disciplines: (1) the federal government — the Health Care Financing Administration, the Office of Health Technology Assessment of the Department of Health and Human Services, the Office of Technology Assessment of the Congress, the National Institutes of Health (NIH), the Veterans Administration, and . . .

This publication has 0 references indexed in Scilit: